Home Symposiums / Research Seminars / Workshop

Research Seminar (21 May 2012)



Research Seminar

How to Solve Genetic Disease on a
Population Scale


Dr Barry Merriman

Lead System Architect, Advanced DNA Sequencing Technology, Life Technologies, Inc.
Visiting Professor, Department of Human Genetics, UCLA

21 May 2012 (Monday)

2:00 – 3:00pm

Room 7-03, 7/F,

The Hong Kong Jockey Club Building for Interdisciplinary Research

5 Sassoon Road, Pokfulam, Hong Kong



I will discuss the latest advances in human genome sequencing technology, especially around the history and status of the new Ion Torrent Proton Platform which promises to be the first to bring the $1000 genome to the market in 2012, and how this can be applied in a systematic way to solve genetic diseases for entire populations. For this I will present a process that identifies and removes all the bottlenecks in deploying genomic personalized medicine for an entire country. Examples will be provided based on specific efforts already underway, and I will discuss the requirements that make countries or regions good candidates for this approach, and the opportunities for such countries to begin and accelerate the process.


Speaker Bio-sketch:

Dr Merriman's academic research focus has been on genomics, both technology development and applications of genomic techniques to solving disease genetics. His role at Life Technologies, the leading global provider of Life Science tools, has been to architect their roadmap for sequencing technology and new applications. This in particular included leading the acquisition of the Ion Torrent semiconductor chip-based technology, the largest acquisition of DNA sequencing technology in history, and presently leading the efforts to deploy this technology for large scale translational and clinical applications nationally in the US and globally.



Kind Reminder: Please take off your lab coat before coming to the seminar.

Refreshment to be served

For enquiries, please call 2831-5500 or write to This e-mail address is being protected from spambots. You need JavaScript enabled to view it